ECE2014 Poster Presentations Thyroid Cancer (70 abstracts)
Prognostic significance of TERT promoter mutations in follicular cell-derived thyroid carcinomas
Miguel Melo 1, , Adriana Gaspar da Rocha 1, , João Vinagre 1, , Rui Batista 1 , Joana Peixoto 1 , Ricardo Celestino 1 , Catarina Salgado 1 , Catarina Eloy 1 , Jorge Lima 1, , Teresina Amaro 6 , Cláudia Lobo 7 , Margarida Moura 8, , Branca Cavaco 8, , Valeriano Leite 8, , José Manuel Cameselle-Teijeiro 11 , Francisco Carrilho 2 , Manuela Carvalheiro 2 , Valdemar Máximo 1, , Manuel Sobrinho-Simões 1, & Paula Soares 1,
1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal; 2Department of Endocrinology, Diabetes and Metabolism, Center of Coimbra, University and Hospital, Coimbra, Portugal; 3Medical Faculty, University of Porto, Porto, Portugal; 4Institute of Biomedical Sciences of Abel Salazar, University of Porto, Porto, Portugal; 5Department of Pathology and Oncology, Medical Faculty, University of Po, Porto, Portugal; 6Department of Pathology, Hospital Pedro Hispano, Matosinhos, Portugal; 7Department of Pathology, Portuguese Institute of Oncology – Porto Center, Porto, Portugal; 8Portuguese Institute of Oncology – Lisbon Center, Center for Investigation of Molecular Pathobiology, Lisboa, Portugal; 9Faculty of Medical Sciences, Center for the Study of Chronic Diseases, University of Lisbon, Lisboa, Portugal; 10Department of Endocrinology, Portuguese Institute of Oncology – Lisbon Center, Lisboa, Portugal; 11Department of Pathology, Medical Faculty, Clinical University Hospital, SERGAS, University of Santiago de Compostela, Santiago de Compostela, Spain; 12Department of Pathology, Hospital S João, Porto, Portugal.
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers.
Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTC).
Material and Methods: We studied 647 tumours and tumour-like lesions. A total of 469 patients with FCDTC treated and followed in five University Hospitals were included. Mean follow-up (±S.D.) was 7.8±5.8 years. We evaluate the predictive value of TERT promoter mutations and other clinico-pathological and molecular features (BRAF, NRAS) for distant metastasization, disease persistence at the end of follow-up and disease-specific mortality.
Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTC), 17.1% of follicular carcinomas (FTC), 29.0% of poorly differentiated carcinomas and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumours were older (P<0.001) and had larger tumours (P=0.002). In DTC, TERT promoter mutations were significantly associated with distant metastases (P<0.001) and higher stage (P<0.001). Patients with DTC harbouring TERT promoter mutations were submitted to more radioiodine treatments (P=0.009) with higher cumulative dose (p=0.004), and to more treatment modalities (P=0.001). At the end of follow-up, patients with TERT-mutated DTC were more prone to have persistent disease (P=0.001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P<0.001)] in DTC (P<0.001), in PTC (P=0.001) and in FTC (P<0.001). After adjusting for age at diagnosis and gender, the HR was 10.35 (95%CI 2.01–53.24; P=0.005) in DTC and 23.81 (95%CI 1.36–415.76; P=0.03) in PTC.
Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumours, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more